Advertisement

TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Posted: 02/08/2022 | By: Chase Doyle

Question 1 of 5

Which subset of patients demonstrated the most benefit from the addition of durvalumab to gemcitabine/cisplatin?

Choose 1

A
Those with intrahepatic cholangiocarcinoma
B
Those with extrahepatic cholangiocarcinoma
C
Those with gallbladder cancer
D
Those with metastatic disease at diagnosis

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage